Navigation Links
Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
Date:4/29/2009

ANTONY, France, April 29 /PRNewswire-FirstCall/ -- Stallergenes S.A. announces the release of the first year outcome of its phase IIb/III clinical trial (VO 57.07) on a sublingual house dust mite desensitization tablet.

"We are very pleased with the outcome of this study, which is the first large study to ever demonstrate the efficacy of house dust mites allergen in treating perennial allergic rhinitis. Furthermore, the unexpected quick onset of action and the good safety profile are addressing the needs of patients with moderate to severe forms of the disease. This study will be pivotal in the European registration process of our house dust mites sublingual tablet, and the basis for further developments in our program" states Albert Saporta, Chairman and CEO of Stallergenes. "This study is a genuine landmark which confirms desensitization as a new therapeutic class in the management of allergic respiratory disorders. Stallergenes has been consolidating its leadership in this field through its innovative and development capabilities".

Stallergenes has been conducting a phase IIb/III clinical trial, with a sublingual tablet in adults suffering from moderate to severe persistent allergic rhinitis to house dust mites, including 509 patients, over seven countries, with a full year of treatment from January to December 2008. This study compared two treated groups, one with a daily intake of 300 IR[1] sublingual tablet, the other of 500 IR, with a placebo group. The endpoint was the adjusted average symptom score on nasal symptoms assessed during the three last months of the year.

The two treated groups have demonstrated a highly significant statistical difference on the primary endpoint versus the placebo group (p less than or equal to 0.0136), with no difference between the two treated groups. In the different groups, use of rescue medication was allowed throughout the period. The adjusted avera
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
2. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
3. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
4. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
5. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
6. Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
9. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
10. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
11. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... Extensiv hydrolysierte Milch ... Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ist die ... Kleinkindern. Der bisher übliche Umgang mit dieser ... bzw. deren stillenden Mütter Milchproteine zu vermeiden. ... einer beträchtlichen Anzahl von Kindern der Aufbau ...
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
... 2011 Aethlon Medical, Inc. (OTCBB: ... to address infectious disease and cancer, announces that ... a company overview, discuss recent developments and review ... & Medical Technologies Virtual Conference.   ...
... June 7, 2011 CMR Institute , the leading ... announces the addition of two new e-modules to help representatives ... (ACA): The Affordable Care ... Accountable Care Organizations and Future Healthcare Delivery ...
Cached Medicine Technology:Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 2Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 3CMR Institute Adds e-Modules Addressing Healthcare Reform's Impact on Pharmaceutical Industry 2
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
(Date:10/30/2014)... 2014 USARAD Holdings Inc ... and specialty telemedicine solutions provider, including SecondOpinions.com ... existing teleradiology services at Mission Bend ER, it ... telemedicine services, to the state-of-the-art, 24/7, freestanding ER ... of this innovative partnership, there will be many ...
(Date:10/30/2014)... 2014 The annual meeting of ... a close on Saturday, October 18th, marking the end ... in 1989. NAMS is North America’s leading non-profit organization ... of all women during midlife and beyond through an ... physicians and thought leaders from fields as varied as ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- When it comes ... likely than men to delay care when they have symptoms ... someone comes to the hospital with a more severe or ... options available," study author Catherine Kreatsoulas, a Fulbright Scholar and ... in a news release from the Heart and Stroke Foundation ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... of milk could be bad for your health, a new ... in milk can help strengthen bones and prevent osteoporosis. These ... recommend milk as part of a healthy diet. But ... did not protect men or women from bone fractures, and ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... taking too much supplemental calcium are on the rise, ... of the Journal of the American Society Nephrology ... calcium-alkali syndrome is growing in large part because of ... The milk-alkali syndrome arose in the early 1900s ...
... rural southern Asia are exposed every day to unsafe levels ... doubles their risks for cancer, causes cardiovascular disease, and inhibits ... The World Health Organization (WHO) has referred to the situation ... as "the largest mass poisoning of a population in history." ...
... Experts are now recommending that low-dose aspirin therapy to prevent ... younger than 50 and women younger than 60, who have ... aspirin. The new recommendations are based on an analysis ... side effects such as stomach bleeding, and to a much ...
... found if young adults were more fit, 34% of high ... (HealthDay News) -- Low levels of physical activity and fitness ... 20-year study of young adults shows. , The study, released ... print issue of the journal Hypertension , found that ...
... to play in disease detection , TUESDAY, June 1 (HealthDay ... signs of prostate cancer in human urine, adding to the ... friend. , Some scientists have questioned similar reports of dogs ... lead author of this latest study said the findings are ...
... patients who,ve been told to rest and avoid exercise can ... both during and after treatment, according to new national guidelines. ... Biostatistics and a member of the Abramson Cancer Center at ... guidelines at an educational session at the 2010 meeting of ...
Cached Medicine News:Health News:Calcium supplements: too much of a good thing? 2Health News:Researchers offer solutions to poisonous well-water crisis in southern Asia 2Health News:Researchers offer solutions to poisonous well-water crisis in southern Asia 3Health News:Aspirin recommendations changed for many younger diabetic patients 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 3Health News:Dog Sniffs Out Prostate Cancer in Small Study 2Health News:New cancer guidelines: Exercise during and after treatment is now encouraged 2Health News:New cancer guidelines: Exercise during and after treatment is now encouraged 3
... EBV laboratory diagnosis is generally confirmed by a ... the disease however, is not indicated by the ... in 10 - 20 percent of children. ... necessary to fully ascertain the stage of EBV ...
... Bard® Biopsy Instrument and Needle is specially ... goal: a large quality, reliable core sample. ... featuring ultra-sharp tips and polished surfaces for ... of biopsy systems and needle sizes assures ...
... to bring efficiency and quality to routine ... superior technology of fluorescent flow cytometry with ... sampling or batch processing are easily accommodated ... in high volume laboratories. Fluorescent flow ...
... The IsoSleeve™ Source Delivery System incorporates ... design that provides the confidence that each ... prior to implant. Unlike other preloaded needle ... verification of the loading configuration giving you ...
Medicine Products: